|
Volumn 15, Issue 4, 2007, Pages 1679-1693
|
Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists
|
Author keywords
Integrin; Oral availability; VLA 4
|
Indexed keywords
4 [1 [3 BROMO 4 [N' (2 BROMOPHENYL)UREIDO]PHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [1 [3 BROMO 4 [N' (2 CHLOROPHENYL)UREIDO]PHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [1 [3 BROMO 4 [N' (2 METHYLPHENYL)UREIDO]PHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [1 [3 CHLORO 4 [N' (2 CHLOROPHENYL)UREIDO]PHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [1 [3 CHLORO 4 [N' (2 METHYLPHENYL)UREIDO]PHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [1 [3 ETHYL 4 [N' (2 METHYLPHENYL)UREIDO] 3 METHYLPHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [1 [3 ISOPROPYL 4 [N' (2 METHYLPHENYL)UREIDO] 3 METHYLPHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [1 [4 [N' (2 BROMOPHENYL)UREIDO] 3 CHLOROPHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [1 [4 [N' (2 BROMOPHENYL)UREIDO] 3 METHOXYPHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [1 [4 [N' (2 BROMOPHENYL)UREIDO] 3 METHYLPHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [1 [4 [N' (2 CHLOROPHENYL)UREIDO] 3 METHOXYPHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [1 [4 [N' (2 CHLOROPHENYL)UREIDO] 3 METHYLPHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [1 [4 [N' (2 METHYLPHENYL)UREIDO] 3 TRIFLUOROMETHYLPHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [FLUORO 1 [3 METHOXY 4 [N' (2 TRIFLUOROMETHYLPHENYL)UREIDO] 3 METHOXYPHENYLACETYL]FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [FLUORO 1 [3 METHYL 4 [N' (2 METHYLPHENYL)UREIDO] 3 METHOXYPHENYLACETYL]FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [FLUORO 1 [4 [N' (2 ISOPROPYLPHENYL)UREIDO] 3 METHOXYPHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
4 [FLUORO 1 [4 [N' (2 METHOXYPHENYL)UREIDO] 3 METHOXYPHENYLACETYL] FLUOROPYRROLIDINYLMETHOXY]BENZOIC ACID;
BENZENE;
BENZOIC ACID DERIVATIVE;
BROMINE;
CHLORINE;
RECEPTOR BLOCKING AGENT;
UNCLASSIFIED DRUG;
UREA DERIVATIVE;
VERY LATE ACTIVATION ANTIGEN 4 ANTAGONIST;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ARTICLE;
CONTROLLED STUDY;
DOG;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG CLEARANCE;
DRUG POTENCY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
FEMALE;
IC 50;
MALE;
MOUSE;
NONHUMAN;
RAT;
ADMINISTRATION, ORAL;
ANIMALS;
BENZOIC ACIDS;
DISEASE MODELS, ANIMAL;
DOGS;
INFLAMMATION;
INHIBITORY CONCENTRATION 50;
INTEGRIN ALPHA4BETA1;
MICE;
PHARMACOKINETICS;
PLEURISY;
RATS;
STRUCTURE-ACTIVITY RELATIONSHIP;
CANIS FAMILIARIS;
MUS;
RATTUS;
|
EID: 33847770256
PISSN: 09680896
EISSN: None
Source Type: Journal
DOI: 10.1016/j.bmc.2006.12.006 Document Type: Article |
Times cited : (15)
|
References (35)
|